Condition: Cirrhosis · Sponsor: Institute of Liver and Biliary Sciences, India
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.
This description comes directly from the study's public registry record.
Dr Ankur Jindal, DM · 011-46300000 · ankur.jindal3@gmail.com
Dr Ankit Bhardwaj, PhD (Epidemiology) · 01146300000 · bhardwaj.ankit3@gmail.com
Always discuss trial participation with your own doctor first.
| Institute of Liver & Biliary Sciences (ILBS) | New Delhi, National Capital Territory of Delhi, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01212250